NuWave Investment Management LLC grew its stake in Allergan plc (NYSE:AGN) by 186.3% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 816 shares of the company’s stock after buying an additional 531 shares during the quarter. NuWave Investment Management LLC’s holdings in Allergan were worth $137,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Liberty Wealth Management LLC boosted its holdings in Allergan by 35.3% during the second quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock worth $43,000 after purchasing an additional 67 shares during the last quarter. TRUE Private Wealth Advisors boosted its holdings in Allergan by 4.5% during the third quarter. TRUE Private Wealth Advisors now owns 1,715 shares of the company’s stock worth $288,000 after purchasing an additional 74 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in Allergan by 43.1% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 259 shares of the company’s stock worth $44,000 after purchasing an additional 78 shares during the last quarter. Nwam LLC boosted its holdings in Allergan by 2.1% during the third quarter. Nwam LLC now owns 4,888 shares of the company’s stock worth $823,000 after purchasing an additional 99 shares during the last quarter. Finally, Old North State Trust LLC boosted its holdings in Allergan by 172.4% during the third quarter. Old North State Trust LLC now owns 158 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 80.52% of the company’s stock.
Several research analysts recently commented on the stock. JPMorgan Chase & Co. set a $200.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Wednesday, June 19th. UBS Group increased their target price on shares of Allergan from $172.00 to $189.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. Svb Leerink restated a “market perform” rating and set a $188.00 target price (down previously from $217.00) on shares of Allergan in a report on Thursday, July 18th. TheStreet upgraded shares of Allergan from a “d+” rating to a “c” rating in a report on Friday, July 12th. Finally, Cantor Fitzgerald increased their target price on shares of Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $179.15.
NYSE AGN opened at $170.92 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.91 and a debt-to-equity ratio of 0.34. The firm’s fifty day moving average price is $165.67 and its two-hundred day moving average price is $152.23. Allergan plc has a 1 year low of $114.27 and a 1 year high of $192.69. The firm has a market capitalization of $55.43 billion, a P/E ratio of 10.24, a price-to-earnings-growth ratio of 2.00 and a beta of 1.65.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.34 by $0.04. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The firm had revenue of $4.09 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same period in the prior year, the firm posted $4.42 earnings per share. The company’s quarterly revenue was down .8% compared to the same quarter last year. On average, research analysts anticipate that Allergan plc will post 16.68 EPS for the current fiscal year.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: Cost of Debt
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.